Sensoorion announces the end of the involvement of patients in the SENS-401 clinical trial for notoxis phase 2a for the prevention of isotoxicity caused by cisplatin

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.